Sign In
Buy PRFX
$1.13
+0.130 (+13.00%)
At Close: Aug 04, 2026
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
11:39am, Friday, 16'th Jan 2026
Penny stock PainReform Ltd. (NASDAQ: PRFX) stock climbed on Friday following the company's recent announcement of a name change to PRF Technologies Ltd.
PainReform Ltd. Changes Name to PRF Technologies Ltd.
04:05pm, Thursday, 15'th Jan 2026
Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as
TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operat
PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison
02:22am, Saturday, 10'th Jan 2026
PainReform (NASDAQ: PRFX - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the t
New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperforma
BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week
08:48am, Tuesday, 30'th Dec 2025
AI-driven monitoring and analytics solutions addressing the growing demand for energy efficiency in large-scale solar and critical infrastructure projects across the Middle East. TEL AVIV, Israel, Dec
PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities
08:30am, Wednesday, 10'th Dec 2025
TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio's proprietary drop-less,
PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy
09:15am, Tuesday, 02'nd Dec 2025
Development plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market Development plan positions OcuRing™-K for advancement in the fast-gro
PainReform (NASDAQ:PRFX) Trading Down 1.3% – Here’s Why
02:30am, Tuesday, 18'th Nov 2025
PainReform Ltd. (NASDAQ: PRFX - Get Free Report) dropped 1.3% during mid-day trading on Monday. The stock traded as low as $0.87 and last traded at $0.8838. Approximately 96,867 shares changed hands d
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis
09:00am, Wednesday, 12'th Nov 2025
TEL AVIV, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that DeepSolar, its solar energy business unit developing next-generation AI analytics, has advanced
TEL AVIV, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics,
PainReform Provides Business Update for the Six Months Ended June 30, 2025
09:27am, Wednesday, 01'st Oct 2025
TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of
Nvidia enrollment sends this stock soaring 130%
10:15am, Tuesday, 19'th Aug 2025
Shares of Israel-based pharmaceutical company PainReform (NASDAQ: PRFX) jumped nearly 130% on Tuesday after its renewable energy arm, DeepSolar, was accepted into the Nvidia (NASDAQ: NVDA) Connect Pro
PainReform/DeepSolar Accepted into NVIDIA Connect Program
08:30am, Tuesday, 19'th Aug 2025
Acceptance to NVIDIA Connect Program offers access to unique tools for the development of DeepSolar's nextgen, AI-driven, solar forecasting platform to improve weather prediction accuracy by up to 50%
Acquisition of Majority Equity Interest in LayerBio and its OcuRing™-K Technology Targets Growing Demand for ‘Dropless' Solutions in Ophthalmic Surgery Acquisition of Majority Equity Interest in L
